Researchers identified the drug currently under review by the U.S. Food and Drug Administration, acts on the level of oxidants lining the cardiovascular system and can restore levels of nitric oxide and reduce oxidative stress.
Researchers published their findings in a recent issue of Circulation and found a deficiency in nitric oxide and high oxidative stress can cause a variety of health problems, including heart attacks, stroke and heart failure, as well as kidney failure and diabetes.
Lead researcher Tadeusz Malinski says, "The drug restores correct balance between good nitric oxide and damaging oxidative stress, and can in fact restore the vital function of endothelial tissue to a level similar in other ethnic groups."
He adds, "Previous treatments only slowed progression of the damage, while Nebivolol may actually be able to correct the problems."
